Roche/Ipsen push taspoglutide filing back to 2011
This article was originally published in Scrip
Executive Summary
Roche/Ipsen have announced that they will file the GLP-1 analogue taspoglutide for type 2 diabetes in 2011, back from previous expectations that it would be filed in the fourth quarter of this year.